Leukeran (Chlorambucil)

Chlorambucil, the active ingredient in Leukeran, is an alkylating agent presented as a oral tablet for oral use. It treats certain blood cancers such as chronic lymphocytic leukemia, Hodgkin's lymphoma and non‑Hodgkin lymphoma.

GNH USA supplies Leukeran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Leukeran (chlorambucil) is used in the management of hematologic malignancies that involve abnormal lymphocyte proliferation.

- Chronic lymphocytic leukemia: improves disease control and prolongs survival. - Hodgkin's lymphoma: contributes to remission when combined with other agents. - Non‑Hodgkin lymphoma: reduces tumor burden and can achieve partial or complete response.

Leukeran may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Fatigue: general tiredness. - Myelosuppression: reduced blood cell counts leading to anemia, neutropenia, thrombocytopenia. - Alopecia: hair thinning or loss.

Serious or Rare Side Effects: - Secondary malignancies: risk of developing new cancers. - Severe infection: due to profound neutropenia. - Pulmonary toxicity: interstitial pneumonitis. - Hepatotoxicity: elevated liver enzymes or liver injury.

Before prescribing Leukeran, clinicians should consider several safety precautions. - Baseline blood counts: obtain a complete blood count to assess marrow function. - Renal and hepatic function: evaluate kidney and liver labs as impairment may affect clearance. - Infection risk: monitor for signs of infection due to immunosuppression. - Pregnancy: avoid use in pregnant women unless benefits outweigh risks; discuss contraception. - Concomitant myelosuppressive agents: use caution when combined with other chemotherapy. - Store at ambient temperature: keep tablets below 25°C in the original container, protect from moisture.

Chlorambucil can interact with other medicines, altering its efficacy or toxicity.

Major Interactions (Avoid): - Live vaccines: increased risk of infection; avoid concurrent administration. - Strong CYP450 inducers (e.g., rifampin, carbamazepine): may reduce chlorambucil exposure. - Anticoagulants (warfarin): heightened bleeding risk due to platelet suppression.

Moderate Interactions (Monitor Closely): - Allopurinol: may increase myelosuppression; monitor blood counts. - Azathioprine or other immunosuppressants: additive bone marrow toxicity. - NSAIDs: may exacerbate gastrointestinal irritation.